Qualigen Therapeutics Provides Update on Developments at NanoSynex; Significant Progress Reported on Infectious Disease Diagnostic Platform
CARLSBAD, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq:QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today shares an update on its majority-owned subsidiary, NanoSynex Ltd. (“NanoSynex”), the progress made during 2022, and objectives for 2023 concerning the commercialization plans for its innovative rapid Antimicrobial Susceptibility Test (AST).
Related news for (QLGN)
- MoBot alert highlights: NASDAQ: VIOT, NASDAQ: GNTA, NASDAQ: QLGN, NASDAQ: VIVK, NASDAQ: ADTX (10/24/25 06:00 AM)
- MoBot’s Stock Market Highlights – 10/24/25 05:00 AM
- Today’s Top Performers: MoBot’s Market Review 10/24/25 04:00 AM
- Today’s Top Performers: MoBot’s Market Review 10/23/25 05:00 PM
- Qualigen Therapeutics Partners with BitGo to Execute First Multi-Asset C10 Treasury Allocation
